5 Biggest Genomics Companies In The World

3. Natera, Inc. (NASDAQ: NTRA)

Market Capitalization: $4.56 billion

Number of Hedge Fund Holders: 39

Based in Austin, Texas, Natera, Inc. (NASDAQ: NTRA) is a global provider of cell-free DNA (cfDNA) testing services with more than 100 peer-reviewed research publications. The company has a dedicated commercial team and undertakes persistent research and development efforts to attain expansion in a sizable, underpenetrated market. It has an employee base of 2,670 individuals.

On October 27, 2022, David Westenberg, an analyst at Piper Sandler, named Natera, Inc. (NASDAQ: NTRA) as his best stock in minimal residual disease. The investor stated in a research note that Natera, Inc. (NASDAQ: NTRA) has plenty of room for growth, with the TAM of minimal residual disease market increasing to over $10 billion recently. The analyst stated that the market is growing rapidly and is expected to reach $93 billion by 2027, and Natera, Inc. (NASDAQ: NTRA) boasts a first-mover advantage and is well-positioned to increase its market share.

Here is what Baron Global Advantage Fund has to say about Natera, Inc. (NASDAQ:NTRA) in its Q1 2022 investor letter:

Natera, Inc. is a leader in non-invasive prenatal testing whose proprietary technology has also been applied to cancer recurrence detection. Shares dropped 67% during the quarter on disappointing quarterly results and a short report alleging aggressive sales practices. We sold our shares as the inflection point to profitability will take longer to materialize, resulting in heavier cash burn rates than we originally expected.

39 hedge funds were long on the company’s stock at the end of the second quarter, according to Insider Monkey database. Holocene Advisors was the biggest stakeholder of the company at the end of Q2 2022, with a holding of 2,983,154 shares.